Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Alpine Immune Sciences Inc
(NQ:
ALPN
)
64.67
+0.08 (+0.13%)
Streaming Delayed Price
Updated: 3:22 PM EDT, May 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Alpine Immune Sciences Inc
< Previous
1
2
3
4
5
6
7
Next >
ALPN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Alpine Immune Sciences, Inc. Is Fair to Shareholders
April 10, 2024
From
Halper Sadeh LLC
Via
Business Wire
Vertex Pharmaceuticals Nabs Alpine Immune Sciences In $4.9 Billion Deal
April 10, 2024
The companies expect the deal to close later this quarter.
Via
Investor's Business Daily
Alpine Immune Sciences Shares Updated Clinical Data from Povetacicept in IgA Nephropathy
April 10, 2024
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
April 10, 2024
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Navigating 8 Analyst Ratings For Alpine Immune Sciences
April 09, 2024
Via
Benzinga
Alpine Immune Sciences Inc. (NASDAQ: ALPN) is a Stock Spotlight on 3/19
March 19, 2024
Via
Investor Brand Network
Why Is Kidney Disease-Focused Alpine Immune Sciences Stock Trading Higher On Wednesday?
April 10, 2024
Alpine Immune Sciences explores strategic options, potentially selling amid interest from buyers. The Seattle-based firm, with soaring stock up over 400%, evaluates various possibilities.
Via
Benzinga
Lamb Weston Reports Weak Earnings, Joins Paragon 28, Resources Connection And Other Big Stocks Moving Lower On Thursday
April 04, 2024
U.S. stocks were higher, with the Dow Jones gaining over 150 points on Thursday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Alpine Immune Sciences to Present Updated Clinical Data for Povetacicept in IgA Nephropathy at the World Congress of Nephrology 2024
April 01, 2024
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences Presents New Translational Data on Povetacicept at the European Lupus Meeting 2024
March 21, 2024
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Evaluating Alpine Immune Sciences: Insights From 6 Financial Analysts
March 19, 2024
Via
Benzinga
Recap: Alpine Immune Sciences Q4 Earnings
March 18, 2024
Via
Benzinga
Alpine Immune Sciences to Participate in Upcoming H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
March 20, 2024
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Why Peraso Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
March 19, 2024
Shares of Peraso Inc. (NASDAQ: PRSO) fell sharply during Tuesday’s session after the company reported worse-than-expected fourth-quarter EPS results.
Via
Benzinga
Preview: Alpine Immune Sciences's Earnings
March 15, 2024
Via
Benzinga
Alpine Immune Sciences Inc. (NASDAQ: ALPN) is a Stock Spotlight on 3/8
March 08, 2024
Via
Investor Brand Network
Alpine Immune Sciences Inc. (NASDAQ: ALPN) is a Stock Spotlight on 2/29
February 29, 2024
Via
Investor Brand Network
In-Depth Examination Of 6 Analyst Recommendations For Alpine Immune Sciences
January 26, 2024
Via
Benzinga
Alpine Immune Sciences Analysts Boost Their Forecasts After Q4 Earnings
March 19, 2024
Alpine Immune Sciences, Inc. (NASDAQ: ALPN) reported better-than-expected fourth-quarter financial results.
Via
Benzinga
National CineMedia Reports Upbeat Results, Joins Nordstrom, Core & Main And Other Big Stocks Moving Higher On Tuesday
March 19, 2024
U.S. stocks were mixed, with the Dow Jones index gaining around 75 points on Tuesday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
ALPN Stock Earnings: Alpine Immune Sciences Beats EPS, Beats Revenue for Q4 2023
March 18, 2024
ALPN stock results show that Alpine Immune Sciences beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.
Via
InvestorPlace
Alpine Immune Sciences Provides Corporate Update and Full Year 2023 Financial Results
March 18, 2024
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Beyond The Numbers: 7 Analysts Discuss Alpine Immune Sciences Stock
December 22, 2023
Via
Benzinga
Earnings Scheduled For March 18, 2024
March 18, 2024
Companies Reporting Before The Bell • Niu Techs (NASDAQ:NIU) is expected to report earnings for its fourth quarter.
Via
Benzinga
Alpine Immune Sciences to Report Fourth Quarter and Full Year 2023 Financial Results
March 07, 2024
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences to Participate in Two Upcoming Healthcare Conferences
February 26, 2024
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences to Participate in Two Upcoming Healthcare Conferences
February 01, 2024
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Why Humana Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
January 25, 2024
Shares of Humana Inc. (NYSE: HUM) fell sharply during Thursday’s session after the company reported fourth-quarter FY23 earnings and issued 2024 guidance.
Via
Benzinga
Alaska Air Posts Upbeat Earnings, Joins Xerox, United Rentals And Other Big Stocks Moving Higher On Thursday
January 25, 2024
U.S. stocks traded higher, with the Dow Jones gaining around 50 points on Thursday. Shares of Alaska Air Group, Inc. (NYSE: ALK) rose during Thursday’s session following upbeat earnings.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Tesla To Rally Around 38%? Here Are 10 Top Analyst Forecasts For Friday
December 22, 2023
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.